

# Development for immunotherapeutics targeting tumor-associated macrophages

AIMEDBIO



ONCOLOGY	Lead
Product Type	Fully human IgG1, afucosylated
Indication	Brain cancer, Lung cancer
Target	Tumor-associated macrophage
MoA(Mechanism of Action)	Selective depletion of “M2-like “TAMs
Competitiveness	<ul style="list-style-type: none"> <li>• Differentiated binding site</li> <li>• Superior binding affinity and ADCC activity</li> </ul>
Development Stage	Lead
Route of Administration	Intravenous